About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
https://weizmann-usa.org/news-media/news-releases/uncovering-the-anti-myeloma-resistance-files/
Feb 23, 2021... REHOVOT, ISRAEL—February 23, 2021—Multiple myeloma patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most people develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science researchers, in collaboration with physicians from Tel Aviv Sourasky Medical Center (TASMC), have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma. Their study, reported in Nature Medicine, may lead to a more informed, personalized treatment for these patients, and paves the way for using this new technology to discover disease targets in other cancers.
Feb 28, 2021...
Researchers from the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center have found 30 genes that seem to be responsible for the resistance that multiple myeloma shows to treatment, which may help lead to more informed, personalized treatment for patients.
Malignant myeloma is a cancer of the antibody-producing plasma cells in bone marrow. Most patients develop resistance to medications and in some, the cancer is resistant to therapy from the start.
Apr 14, 2021... REHOVOT, ISRAEL—April 14, 2021—Being constantly hungry, no matter how much you eat – that’s the daily struggle of people with genetic defects in the brain’s appetite controls, and it often ends in severe obesity. In a study published in Science, researchers at the Weizmann Institute of Science, together with colleagues from the Queen Mary University of London and the Hebrew University of Jerusalem, have revealed the mechanism of action of the master switch for hunger in the brain: a receptor called melanocortin 4 (MC4). They have also clarified how this switch is activated by setmelanotide (brand name Imcivree), a drug recently approved for the treatment of severe obesity caused by certain genetic changes. The team’s findings shed new light on the way hunger is regulated and may help develop improved anti-obesity medications.
Apr 21, 2021...
Scientists may have discovered how a “switch” in the brain controls appetite, raising hopes for a new class of anti-obesity drugs.
Many people would like to lose a few pounds, with the temptation of favourite dishes and snacks often proving too much for our willpower.
For some, however, genetic defects cause them to feel famished no matter how much food they consume, resulting in severe obesity.
https://weizmann-usa.org/news-media/news-releases/insulin-making-cells-discovered-in-the-fetal-gut/
Dec 09, 2021... REHOVOT, ISRAEL—December 9, 2021—An exclusive “license” for making insulin in the human body belongs to the beta cells scattered throughout the pancreas. But because beta cells can become scarce or dysfunctional in people with diabetes, scientists have been searching for other cells that might be coaxed into manufacturing the vital glucose-regulating hormone. In a study published today in Nature Medicine, researchers from the Weizmann Institute of Science and from Yale School of Medicine discovered insulin-making cells in an unexpected place, the fetal intestine. This discovery may open up new directions in the future development of potential treatments for diabetes.
https://weizmann-usa.org/news-media/news-releases/tracking-multiple-genes-with-flying-colors/
Jan 31, 2022...
REHOVOT, ISRAEL—January 31, 2022—Even fans of black-and-white film can’t deny that color brought new life to photography and motion pictures. And when it comes to learning what happens inside the body, there’s no substitute for color.
Were it possible, for example, to map out real-time gene expression in our body’s cells using contrasting colors, scientists would gain a glimpse of vital biological processes that are currently invisible. The problem is that the glowing multicolor proteins used by scientists to illuminate, so to speak, the inner workings of cells are of little help in observing deep-seated processes in the body, because the thickness of tissues obscures the glow.
Mar 31, 2022... REHOVOT, ISRAEL—March 31, 2022—Genetic mutations linked to a disease often spell bad news. Mutations in over 25 genes, for example, are associated with amyotrophic lateral sclerosis, or ALS, and they all increase the risk of developing this incurable disorder. Now, a research team headed by Prof. Eran Hornstein of the Weizmann Institute of Science has linked a new gene to ALS, but this one contains mutations of a different sort: They seem to play a defensive, rather than an offensive, role in the disease.
May 25, 2022...
REHOVOT, ISRAEL – May 25 2022 – Our family origins tend to shape our future in many ways. A Weizmann Institute of Science study, published today in Nature, found that the same holds true for blood vessels. The researchers discovered blood vessels forming from unexpected progenitors and went on to show that this unusual origin determines the vessels’ future function.
“We found that blood vessels must derive from the right source in order to function properly – it’s as if they remember where they came from,” says team leader Prof. Karina Yaniv.
https://weizmann-usa.org/news-media/feature-stories/remembering-prof-michael-sela/
May 31, 2022...
The worldwide community of the Weizmann Institute of Science deeply mourns the passing of our beloved longtime leader, preeminent scientist, and dear friend, Prof. Michael Sela.
Throughout his illustrious career, Michael made numerous discoveries that forever changed immunological research, shedding light on the genetic control of the immune response.
He co-invented the blockbuster drug Copaxone® for the treatment of multiple sclerosis as well as three cancer treatment drugs – Erbitux®, Vectibix®, and Portrazza® – which have improved the lives of millions worldwide.
https://weizmann-usa.org/news-media/feature-stories/a-new-gene-linked-to-als/
May 25, 2022... ALS (amyotrophic lateral sclerosis, also known by the name Lou Gehrig’s disease) is a rare – and devastating – neurological disease. Many of us probably didn’t know about it until the Ice Bucket Challenge a few years ago. So what research developments on the disease have been made since then? ALS Awareness Month is a chance to reflect on that and to share a recent discovery at Weizmann that could slow or prevent the disease.
©2023 American Committee for the Weizmann Institute of Science
